Fig. 2.
a Discontinuation of treatment due to any reason. b Discontinuation of treatment due to adverse events. Cumulative treatment discontinuation rates are compared using the log-rank test among groups. Numbers of patients at risk of each group at weeks 0, 4, 8, 12, 16, and 20 are shown. SS the single-strength dosage group, HS the half-strength dosage group, ES the escalation dosage group, LL lower limit, UL upper limit